Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

June 26, 2019

Study Completion Date

September 30, 2019

Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
DRUG

avelumab

Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months

RADIATION

radiotherapy

5 times a week, 7 weeks, total dose 70 Gy

DRUG

cetuximab

loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7

Trial Locations (1)

1066CX

Antoni van Leeuwenhoek, Amsterdam

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT02938273 - Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) | Biotech Hunter | Biotech Hunter